Thursday, December 12, 2019

CCTG MA.12 – Double-Blind Randomized Trial of Tamoxifen versus Placebo in Patients with Node Positive or High Risk Node Negative Breast Cancer Who Have Completed CMF, CEF, or AC Adjuvant Chemotherapy

**Time:** Thursday, December 12, 2019: 7:00 – 9:00 AM  
**Location:** Hall 1  
**Type:** Poster  
**Session:** Poster Session 2 (7:00 – 9:00 AM)  
**Abstract:** Predictive significance of an optimized immunohistochemical panel for basal-like breast cancer on the CCTG MA.12 phase III randomized clinical trial.  
**Abstract #:** P2-11-03  
**Authors:** Asleh K, Gao D, Bramwell VH, Tu D, Shepherd LE, Nielsen TO.  
**Link:** [https://www.abstractsonline.com/pp8/#!/7946/presentation/721](https://www.abstractsonline.com/pp8/#!/7946/presentation/721)

CCTG IND.231 - A Phase I Study of CX5461

**Time:** Thursday, December 12, 2019: 7:00 – 9:00 AM  
**Location:** Stars at Night Ballroom 1&2  
**Type:** Poster  
**Session:** Spotlight Session PD4: Targeting HER2 and DNA Repair  
**Abstract:** Canadian Cancer Trials Group IND.231: A phase I trial evaluating CX-5461, a novel first-in-class G-quadruplex stabilizer in patients with advanced solid tumours enriched for DNA-repair deficiencies  
**Abstract #:** PD4-02  
**Link:** [https://www.abstractsonline.com/pp8/#!/7946/presentation/1972](https://www.abstractsonline.com/pp8/#!/7946/presentation/1972)